Herren Drugs & Pharmaceuticals Limited was incorporated as a private
limited company on November 29, 1984 and was subsequently converted
to a public limited company on August 29, 1992 for the manufacture of
The company commenced its commercial production in October, 1989 with
an installed capacity of 72 TPA and has increased its capacity to 252
TPA in Sept, 1993 and has been involved in the production of
Ibuprofen, Sulphamethoxazole (SMX), Norfoxacin and Pefloxacin.
SUBSIDIARY OF THE COMPANY
The Company does not have any subsidiaries.
HERREN DRUGS & PHARMACEUTICALS LIMITED is the flagship company of the
Herren Group, founded by Mr.Sarat Gopal.
Besides Herren Drugs a Pharmaceuticals Ltd., Mr.Sarat Gopal has also
successfully promoted four other Bulk Drug and Intermediate
manufacturing units, M/s.Dolphin Drugs (P) Ltd., United
Intermediaries & Chemicals (P) Limited, Dymes Engineers (P) Limited
and M/s.Dymes Exports Ltd.
The Group owes its success and growth largely to its Promoters for
their dynamic vision and total dedication.
With a modest turnover of Rs.25.00 lakhs in the year 1989-90 the
Group has enjoyed a steady growth resulting in a total turnover of
Rs.25.00 crores for the year ended 31st March 1994.
-N Prasad appointed as MD of Matrix Lab.
-Matrix Lab and Medicorp form a strategic alliance to establish a
strong presence in the
Global Active Pharmaceutical Ingredient.
-Matrix Laboratories announces the change in the designation of whole
1. Mr.M Ravinder as Executive Vice-President.
2. Mr R Sundara Rajan as Executive Vice-President.
-Matrix Laboratories completes merger of Vorin Labs and Medicorp
India with it.
-Matrix Lab receives approval from US Food and Drug Administrations
Active Pharmaceutical Ingredient.
-Matrix Lab submits application for drug master files for seven of
the company produts
in the US markets.
-Lundbeck withdraws allegations of Forgery made against Matrix
-Signed agreement with William J Clinton Presidential Foundation for
the supply of Antiretroviral for the treatment of HIV and AIDs
patients in certain developing countries.
To issue 22,50,000 equity shares at Rs 1500/- per share aggregating
to Rs 3375 mn on Preferential basis to Newbridge Capital and other
investors subject to shareholders approval.
To issue 'No Objection' to New Bridge Capital and other investors to
enable them approach Foreign Investment Promotion Board (FIPB), to
obtain their approval for purchase of 18,00,000 equity shares from
the existing shareholders through a secondary sale and
To convene an Extraordinary Meeting of the members of the company on
January 29, 2004 for the aforesaid purpose.
-Gets USFDA nod for manufacturing facility located at Jeedimetlla
-Matrix Labs inks pact with India Newbridge Investments
-Matrix Labs appoints Dr. C Satyanarayana as BoD
-Matrix in strategic alliance with MCHEM of China
- Receives US FDA approval for its Active Pharmaceutical Ingredients
(APIs) manufacturing facility located at Kazipally (Unit-II), near
Hyderabad. Commissioned in 2004, the facility currently manufactures
anti-retrovirals (ARVs) for the treatment of HIV / AIDS.